Secukinumab in the treatment of psoriasis: patient selection and perspectives

References

• GuptaMASchorkNJGuptaAKKirkbySEllisCNSuicidal ideation in psoriasisInt J Dermatol19933231881908444530
   PubMed Web of Science ®Google Scholar
• KurdSKTroxelABCrits-ChristophPGelfandJMThe risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort studyArch Dermatol2010146889189520713823
   PubMed Web of Science ®Google Scholar
• DowlatshahiEAWakkeeMArendsLRNijstenTThe prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysisJ Invest Dermatol201413461542155124284419
   PubMed Web of Science ®Google Scholar
• MehtaNNAzfarRSShinDBNeimannALTroxelABGelfandJMPatients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research DatabaseEur Heart J20103181000100620037179
   PubMed Web of Science ®Google Scholar
• GelfandJMNeimannALShinDBWangXMargolisDJTroxelABRisk of myocardial infarction in patients with psoriasisJAMA2006296141735174117032986
   PubMed Web of Science ®Google Scholar
• RappSRFeldmanSRExumMLFleischerABReboussinDMPsoriasis causes as much disability as other major medical diseasesJ Am Acad Dermatol1999413 Pt 140140710459113
   PubMed Web of Science ®Google Scholar
• GelfandJMTroxelABLewisJDThe risk of mortality in patients with psoriasis: results from a population-based studyArch Dermatol2007143121493149918086997
   PubMed Web of Science ®Google Scholar
• VillaniAPRouzaudMSevrainMPrevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysisJ Am Acad Dermatol201573224224826054432
   PubMed Web of Science ®Google Scholar
• BhutaniTPatelTKooBNguyenTHongJKooJA prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditionsJ Am Acad Dermatol2013692e79e8823207011
   PubMed Web of Science ®Google Scholar
• GelfandJMCommentary: Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality?: A critical question that we are only just beginning to answerJ Am Acad Dermatol2018791697029625133
   PubMed Web of Science ®Google Scholar
• WuJJSundaramMCloutierMThe risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort studyJ Am Acad Dermatol2018791606829499292
   PubMed Web of Science ®Google Scholar
• COSENTYX (secukinumab) [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2016
   Google Scholar
• LangleyRGElewskiBELebwohlMSecukinumab in plaque psoriasis–results of two phase 3 trialsN Engl J Med2014371432633825007392
   PubMed Web of Science ®Google Scholar
• ThaçiDBlauveltAReichKSecukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialJ Am Acad Dermatol201573340040926092291
   PubMed Web of Science ®Google Scholar
• BlauveltAReichKTsaiTFSecukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR studyJ Am Acad Dermatol2017761606927663079
   PubMed Web of Science ®Google Scholar
• MrowietzULeonardiCLGirolomoniGSecukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)J Am Acad Dermatol2015731273625982539
   PubMed Web of Science ®Google Scholar
• BissonnetteRLugerTThaciDSecukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)J Eur Acad Dermatol Venereol20183291507151429444376
   PubMed Web of Science ®Google Scholar
• BlauveltAPrinzJCGottliebABSecukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)Br J Dermatol2015172248449325132411
   PubMed Web of Science ®Google Scholar
• LacourJPPaulCJazayeriSSecukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trialJ Eur Acad Dermatol Venereol201731584785628111801
   PubMed Web of Science ®Google Scholar
• ArmstrongAWVenderRKircikLSecukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular PsoriasisJ Clin Aesthet Dermatol201696 Suppl 1S12s1628439342
   PubMedGoogle Scholar
• SanchezIMSorensonELevinELiaoWThe Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic ReviewDermatol Ther201774425446
   PubMed Web of Science ®Google Scholar
• BagelJDuffinKCMooreAThe effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b studyJ Am Acad Dermatol201777466767428780364
   PubMed Web of Science ®Google Scholar
• GottliebASullivanJvan DoornMSecukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trialJ Am Acad Dermatol2017761708027707593
   PubMed Web of Science ®Google Scholar
• ReichKSullivanJArenbergerPSecukinumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: 16 week results from the TRANSFIGURE study23rd World Congress of DermatologyVancouver, CanadaJune 8–15 2015
   Google Scholar
• ImafukuSHonmaMOkuboYEfficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese studyJ Dermatol20164391011101726919410
   PubMed Web of Science ®Google Scholar
• MeasePJMcinnesIBKirkhamBSecukinumab Inhibition of Interleukin-17A in Patients with Psoriatic ArthritisN Engl J Med2015373141329133926422723
   PubMed Web of Science ®Google Scholar
• McInnesIBMeasePJKirkhamBSecukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet201538699991137114626135703
   PubMed Web of Science ®Google Scholar
• McInnesIBMeasePJRitchlinCTSecukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 studyRheumatology201756111993200328968735
   PubMed Web of Science ®Google Scholar
• KavanaughAMeasePJReimoldAMSecukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled StudyArthritis Care Res2017693347355
   PubMed Web of Science ®Google Scholar
• NashPMeasePJMcinnesIBEfficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)Arthritis Res Ther20182014729544534
   PubMed Web of Science ®Google Scholar
• MeasePvan der HeijdeDLandewéRSecukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 studyAnn Rheum Dis201877689089729550766
   PubMed Web of Science ®Google Scholar
• BlauveltASafety of secukinumab in the treatment of psoriasisExpert Opin Drug Saf201615101413142027545070
   PubMed Web of Science ®Google Scholar
• van de KerkhofPCGriffithsCEReichKSecukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasisJ Am Acad Dermatol2016751839827180926
   PubMed Web of Science ®Google Scholar
• PappKALebwohlMGOnset of Action of Biologics in Patients With Moderate-to-Severe PsoriasisJ Drugs Dermatol201717324725029537442
   PubMed Web of Science ®Google Scholar
• ZschockeIOrtlandCReichKEvaluation of adherence predictors for the treatment of moderate to severe psoriasis with biologics: the importance of physician-patient interaction and communicationJ Eur Acad Dermatol Venereol20173161014102028222230
   PubMed Web of Science ®Google Scholar
• LebwohlMGPappKAMarangellLBPsychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trialsJ Am Acad Dermatol2018781818928985956
   PubMed Web of Science ®Google Scholar
• GottliebABBlauveltAPrinzJCSecukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE TrialJ Drugs Dermatol201615101226123427741340
   PubMed Web of Science ®Google Scholar
• FaustiniFSimonDOliveiraISubclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysisAnn Rheum Dis201675122068207426916344
   PubMed Web of Science ®Google Scholar
• BoydTKavanaughANovel Treatment Concepts in Psoriatic ArthritisRheum Dis Clin North Am201541473975426476230
   PubMed Web of Science ®Google Scholar
• van de KerkhofPCReichKKavanaughAPhysician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis surveyJ Eur Acad Dermatol Venereol201529102002201025885420
   PubMed Web of Science ®Google Scholar
• WuJJFeldmanSRRastogiSMengesBLingohr-SmithMLinJComparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United StatesJ Dermatolog Treat201816
   Google Scholar
• ArmstrongAWBettsKASignorovitchJENumber needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysisCurr Med Res Opin20183471928836861
   PubMed Web of Science ®Google Scholar
• AugustinMMcbrideDGilloteauIO’NeillCNeidhardtKGrahamCNCost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in GermanyJ Eur Acad Dermatol Venereol2018 [Epub ahead of print]
   Web of Science ®Google Scholar
• KromerCCelisDSonntagDPeitschWKBiologicals and small molecules in psoriasis: A systematic review of economic evaluationsPLoS One2018131e018976529298315
   PubMed Web of Science ®Google Scholar
• HamiltonMPNtaisDGriffithsCEDaviesLMIdentification and Management of Psoriasis-Associated ComorbidiTy (IMPACT) TeamPsoriasis treatment and management - a systematic review of full economic evaluationsBr J Dermatol2015172357458325324036
   PubMed Web of Science ®Google Scholar
• YangEJSanchezIMBeckKSekhonSWuJJBhutaniTGuselkumab for the treatment of moderate-to-severe plaque psoriasisExpert Rev Clin Pharmacol201811433334429478344
   PubMed Web of Science ®Google Scholar